{
    "organizations": [],
    "uuid": "e3fbb3aa7955be038b0eb22ed2d5837ac49d2d7c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cymabay-therapeutics-says-first-pr/brief-cymabay-therapeutics-says-first-primary-biliary-cholangitis-patients-have-been-successfully-enrolled-in-seladelpar-long-term-extension-study-idUSFWN1P30PL",
    "ord_in_thread": 0,
    "title": "BRIEF-Cymabay Therapeutics Says First Primary Biliary Cholangitis Patients Have Been Successfully Enrolled In Seladelpar Long-Term Extension Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Cymabay Therapeutics Inc:\n* CYMABAY THERAPEUTICS INC - FIRST PRIMARY BILIARY CHOLANGITIS PATIENTS HAVE BEEN SUCCESSFULLY ENROLLED IN SELADELPAR LONG-TERM EXTENSION STUDY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:08:00.000+02:00",
    "crawled": "2018-01-09T17:15:33.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "cymabay",
        "therapeutic",
        "inc",
        "cymabay",
        "therapeutic",
        "inc",
        "first",
        "primary",
        "biliary",
        "cholangitis",
        "patient",
        "successfully",
        "enrolled",
        "seladelpar",
        "extension",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}